Findings presented at Royal College of Psychiatrists International Congress (RCPsych 2023) confirm the importance of SPRAVATO® as a therapeutic option for adults with treatment-resistant major depressive disorder in patients with 2 and >3 prior treatment failures.1 10 July 2023: The Janssen Pharmaceutical Companies of Johnson & Johnson announced further findings from the ESCAPE-TRD study. Data…
Improvements in treatment of intracranial aneurysms
Meta-analysis shows fewer complications and higher occlusion rates for ruptured wide-neck intracranial aneurysms, using Rapid Medical’s COMANECI™ Embolisation Assist Device 19 July 2023: Rapid Medical™, developer of advanced neurovascular devices, has announced new clinical data showing significant advantages of its novel COMANECI™ embolisation assist device over established techniques to treat ruptured wide-neck intracranial aneurysms. A recent meta-analysis…
Subcutaneous Ocrevus injection – OCARINA II trial results
Phase III trial results could strengthen Ocrevus’s position in multiple sclerosis GlobalData, 19th July 2023: Genentech recently announced positive results from its phase III trial, OCARINA II (NCT05232825), investigating the efficacy of Ocrevus (ocrelizumab) as a subcutaneous injection, administered twice yearly for ten minutes, in patients diagnosed with relapsing multiple sclerosis (RMS) and primary progressive…
Digital biomarker platform for early and differential diagnosis of Parkinson’s disease
BrainTale has been developing non-invasive, accessible, effective and clinically validated measurement and prediction tools for patients suffering from brain diseases BrainTale, a medtech deciphering white matter to enable better brain care, presented preliminary results demonstrating the effectiveness of its digital biomarker platform for the early and differential diagnosis of Parkinson’s disease. Results were presented during…
Buntanetap in PD faces challenges despite phase III progress
Annovis Bio recently received a positive safety review for the Phase III trial of buntanetap in patients with early Parkinson’s Disease (PD) (NCT05357989) from the Data and Safety Monitoring Board (DSMB). Should buntanetap demonstrate good efficacy and safety profiles in the trial, it could be the first α-synuclein-targeting product to enter the market and one…
Concussion guidance for teachers and parents
N-ABLES produces ‘Return-to-School’ concussion guide Easy-to-use, concise guidance for the return-to-school (RTS) following concussion has been produced by UKABIF National Acquired Brain Injury Learning and Education Syndicate (N-ABLES). This two-page document entitled ‘Concussion Return-to-School Guidance’ reiterates the staged return-to-education advocated in the Government’s new grassroots sports guidance but is aimed directly at teachers and parents…
Magstim Horizon 3.0 Transcranial Magnetic Stimulation now in UK
Approval by UKCA Empowers UK physicians to advance care of Treatment Resistant Depression, Obsessive Compulsive Disorder, and Anxious Depression with non-invasive brain stimulation The advanced and FDA-cleared Magstim Horizon 3.0 transcranial magnetic stimulation (TMS) system is now UKCA registered and available for sale in the UK, providing physicians with a proven precision therapy to improve…
FDA approves LEQEMBI™ (lecanemab-irmb)
Traditional approval for the treatment of Alzheimer’s disease in the US July 6, 2023: Eisai Co Ltd and Biogen Inc have announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous use, making LEQEMBI the first and…
Real-world study on AJOVY® reveals sustained long-term effectiveness in migraine
Data presented at the European Academy of Neurology Congress 2023: Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine JULY 2023, TEL AVIV, Israel: Teva Pharmaceutical Industries Ltd has announced further positive data from…
